Artios Pharma

Artios is a leading DNA Damage Response (DDR) company developing a broad-based DDR platform and small molecule drug discovery capabilities to develop a variety of candidate products for cancer treatment. The company is led by an experienced scientific and leadership team with extensive expertise in DDR drug discovery, including the discovery and early development of the PARP inhibitor Olaparib. It has established a unique partnership with Cancer Research UK (CRUK) and collaborates with globally leading DNA repair researchers at institutions such as The Institute of Cancer Research, London (ICR), The Netherlands Cancer Institute (NKI), and The Francis Crick Institute in London. Artios is building a portfolio of next-generation DDR programs targeting difficult-to-treat cancers, including its ATR inhibitor ART0380, which is in Phase I clinical studies for the treatment of DDR-deficient tumors, and the potentially first-in-class Polθ inhibitor ART4215 for use in both monotherapy and combination therapy.